Advertisement

Yeast Infections After Solid Organ Transplantation

  • Todd P. McCarty
  • Peter G. Pappas
Chapter

Abstract

Invasive infections due to yeast are among the most common infections following solid organ transplantation and account for considerable morbidity and mortality. Infections due to Candida species are most common, accounting for over half of all fungal infections following solid organ transplantation. Cryptococcosis is the next most common yeast infection in organ transplant recipients, and is overall the third most common invasive mycosis in this population. Much of what we know about the management of these infections is extrapolated from observations in the general population or other at-risk populations supplemented by lessons learned specific to solid organ transplantation. As the solid organ transplant population continues to grow larger and live longer, the capacity to prevent, diagnosis, and treat these infections appropriately will become more relevant and challenging.

Keywords

Solid organ transplantation Invasive fungal infections Yeast Candida Cryptococcus Trichosporon Rhodotorula Meningitis Fungemia 

References

  1. 1.
    Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–11. doi: 10.1086/651262.PubMedCrossRefGoogle Scholar
  2. 2.
    Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004–2008. Diagn Microbiol Infect Dis. 2012;74(4):323–31. doi: 10.1016/j.diagmicrobio.2012.10.003.PubMedCrossRefGoogle Scholar
  3. 3.
    Neofytos D, Fishman JA, Horn D, Anaissie E, Chang CH, Olyaei A, Pfaller M, Steinbach WJ, Webster KM, Marr KA. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2010;12(3):220–9. doi: 10.1111/j.1399-3062.2010.00492.x.PubMedCrossRefGoogle Scholar
  4. 4.
    Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, Franks B, Azie NE. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004–2008. PLoS One. 2014;9(7), e101510. doi: 10.1371/journal.pone.0101510.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008–2009. Antimicrob Agents Chemother. 2011;55(2):561–6. doi: 10.1128/aac.01079-10.PubMedCrossRefGoogle Scholar
  6. 6.
    Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol. 2011;49(1):396–9. doi: 10.1128/jcm.01398-10.PubMedCrossRefGoogle Scholar
  7. 7.
    Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4(2):119–28. doi: 10.4161/viru.22913.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Saville SP, Lazzell AL, Chaturvedi AK, Monteagudo C, Lopez-Ribot JL. Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice. Infect Immun. 2008;76(1):97–102. doi: 10.1128/iai.00982-07.PubMedCrossRefGoogle Scholar
  9. 9.
    Ramage G, Rajendran R, Sherry L, Williams C. Fungal biofilm resistance. Int J Microbiol. 2012;2012:528521. doi: 10.1155/2012/528521.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    LaFleur MD, Kumamoto CA, Lewis K. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother. 2006;50(11):3839–46. doi: 10.1128/aac.00684-06.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Kurnatowska I, Pazurek M, Nowicki M. Case of esophagitis in a posttransplant female patient. Ann Transplant. 2007;12(3):39–42.PubMedGoogle Scholar
  12. 12.
    Jones JM, Glass NR, Belzer FO. Fatal Candida esophagitis in two diabetics after renal transplantation. Arch Surg. 1982;117(4):499–501.PubMedCrossRefGoogle Scholar
  13. 13.
    Lockhart SR, Wagner D, Iqbal N, Pappas PG, Andes DR, Kauffman CA, Brumble LM, Hadley S, Walker R, Ito JI, Baddley JW, Chiller T, Park BJ. Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. J Clin Microbiol. 2011;49(7):2404–10. doi: 10.1128/JCM.02474-10.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Guery BP, Arendrup MC, Auzinger G, Azoulay E, Borges Sa M, Johnson EM, Muller E, Putensen C, Rotstein C, Sganga G, Venditti M, Zaragoza Crespo R, Kullberg BJ. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med. 2009;35(1):55–62. doi: 10.1007/s00134-008-1338-7.PubMedCrossRefGoogle Scholar
  15. 15.
    Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD, Karchmer AW. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis. 1994;170(3):644–52.PubMedCrossRefGoogle Scholar
  16. 16.
    Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797–805. doi: 10.1002/hep.21563.PubMedCrossRefGoogle Scholar
  17. 17.
    Lichtenstern C, Hochreiter M, Zehnter VD, Brenner T, Hofer S, Mieth M, Buchler MW, Martin E, Weigand MA, Schemmer P, Busch CJ. Pretransplant model for end stage liver disease score predicts posttransplant incidence of fungal infections after liver transplantation. Mycoses. 2013;56(3):350–7. doi: 10.1111/myc.12041.PubMedCrossRefGoogle Scholar
  18. 18.
    Delgado J, Calvo N, Gomis A, Perez-Flores I, Rodriguez A, Ridao N, Valero R, Sanchez-Fructuoso AI. Candiduria in renal transplant recipients: incidence, clinical repercussion, and treatment indication. Transplant Proc. 2010;42(8):2944–6. doi: 10.1016/j.transproceed.2010.08.019.PubMedCrossRefGoogle Scholar
  19. 19.
    Safdar N, Slattery WR, Knasinski V, Gangnon RE, Li Z, Pirsch JD, Andes D. Predictors and outcomes of candiduria in renal transplant recipients. Clin Infect Dis. 2005;40(10):1413–21. doi: 10.1086/429620.PubMedCrossRefGoogle Scholar
  20. 20.
    Bagnasco SM, Subramanian AK, Desai NM. Fungal infection presenting as giant cell tubulointerstitial nephritis in kidney allograft. Transpl Infect Dis. 2012;14(3):288–91. doi: 10.1111/j.1399-3062.2011.00676.x.PubMedCrossRefGoogle Scholar
  21. 21.
    Westervelt JD, Foster KW, Miles CD. Renal allograft pyelonephritis and fungemia due to Candida krusei. Clin Kidney J. 2014;7(1):79–80. doi: 10.1093/ckj/sft160.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Rex JH. Candida in the peritoneum: passenger or pathogen? Crit Care Med. 2006;34(3):902–3. doi: 10.1097/01.ccm.0000202129.19154.64.PubMedCrossRefGoogle Scholar
  23. 23.
    Montravers P, Dupont H, Gauzit R, Veber B, Auboyer C, Blin P, Hennequin C, Martin C. Candida as a risk factor for mortality in peritonitis. Crit Care Med. 2006;34(3):646–52. doi: 10.1097/01.ccm.0000201889.39443.d2.PubMedCrossRefGoogle Scholar
  24. 24.
    Wood GC, Mueller EW, Croce MA, Boucher BA, Fabian TC. Candida sp. isolated from bronchoalveolar lavage: clinical significance in critically ill trauma patients. Intensive Care Med. 2006;32(4):599–603. doi: 10.1007/s00134-005-0065-6.PubMedCrossRefGoogle Scholar
  25. 25.
    Rello J, Esandi ME, Diaz E, Mariscal D, Gallego M, Valles J. The role of Candida sp. isolated from bronchoscopic samples in nonneutropenic patients. Chest. 1998;114(1):146–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Schaenman JM, Rosso F, Austin JM, Baron EJ, Gamberg P, Miller J, Oyer PE, Robbins RC, Montoya JG. Trends in invasive disease due to Candida species following heart and lung transplantation. Transpl Infect Dis. 2009;11(2):112–21. doi: 10.1111/j.1399-3062.2009.00364.x.PubMedCrossRefGoogle Scholar
  27. 27.
    Hadjiliadis D, Howell DN, Davis RD, Lawrence CM, Rea JB, Tapson VF, Perfect JR, Palmer SM. Anastomotic infections in lung transplant recipients. Ann Transplant. 2000;5(3):13–9.PubMedGoogle Scholar
  28. 28.
    Oude Lashof AM, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, Oborska IT, Rex JH, Kullberg BJ. Ocular manifestations of candidemia. Clin Infect Dis. 2011;53(3):262–8. doi: 10.1093/cid/cir355.PubMedCrossRefGoogle Scholar
  29. 29.
    Nagao M, Saito T, Doi S, Hotta G, Yamamoto M, Matsumura Y, Matsushima A, Ito Y, Takakura S, Ichiyama S. Clinical characteristics and risk factors of ocular candidiasis. Diagn Microbiol Infect Dis. 2012;73(2):149–52. doi: 10.1016/j.diagmicrobio.2012.03.006.PubMedCrossRefGoogle Scholar
  30. 30.
    Dedi R, Kumar A, Chang B, Wright MJ, Brownjohn AM. Candidal endophthalmitis in a renal transplant patient. Nephrol Dial Transplant. 2001;16(3):637–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Papanicolaou GA, Meyers BR, Fuchs WS, Guillory SL, Mendelson MH, Sheiner P, Emre S, Miller C. Infectious ocular complications in orthotopic liver transplant patients. Clin Infect Dis. 1997;24(6):1172–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Del Pozo JL, van de Beek D, Daly RC, Pulido JS, McGregor CG, Patel R. Incidence and clinical characteristics of ocular infections after heart transplantation: a retrospective cohort study. Clin Transplant. 2009;23(4):484–9. doi: 10.1111/j.1399-0012.2009.01026.x.PubMedCrossRefGoogle Scholar
  33. 33.
    Singh N, Huprikar S, Burdette SD, Morris MI, Blair JE, Wheat LJ. Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, infectious diseases community of practice. Am J Transplant. 2012;12(9):2414–28. doi: 10.1111/j.1600-6143.2012.04100.x.PubMedCrossRefGoogle Scholar
  34. 34.
    Addeo P, Saouli AC, Woehl-Jaegle ML, Ellero B, Oussoultzoglou E, Marcellin L, Bachellier P. Candida albicans arteritis transmitted by preservation fluid after liver transplantation. Ann Transplant. 2014;19:64–7. doi: 10.12659/aot.889831.PubMedCrossRefGoogle Scholar
  35. 35.
    Debska-Slizien A, Chrobak L, Bzoma B, Perkowska A, Zadrozny D, Chamienia A, Kostro J, Milecka A, Bronk M, Sledzinski Z, Rutkowski B. Candida arteritis in kidney transplant recipients: case report and review of the literature. Transpl Infect Dis. 2015. doi: 10.1111/tid.12388.PubMedGoogle Scholar
  36. 36.
    Rodrigues BF, Natario AS, Vizinho RS, Jorge CM, Weigert AL, Martinho A, Toscano C, Marques TT, Machado DS. Candida species contamination of preservation fluid-outcome of renal transplantation in 6 patients. Transplant Proc. 2013;45(6):2215–9. doi: 10.1016/j.transproceed.2013.03.024.PubMedCrossRefGoogle Scholar
  37. 37.
    Levesque E, Suet G, Merle JC, Compagnon P, Amathieu R, Feray C, Botterel F, Foulet F, Azoulay D, Dhonneur G. Candida vascular complication in a liver transplant recipient due to yeast contamination of preservation solution. Transpl Infect Dis. 2014;16(5):827–9. doi: 10.1111/tid.12260.PubMedCrossRefGoogle Scholar
  38. 38.
    Veroux M, Corona D, Scriffignano V, Caglia P, Gagliano M, Giuffrida G, Gona F, Sciacca A, Giaquinta A, Oliveri S, Sinagra N, Tallarita T, Zerbo D, Sorbello M, Parrinello L, Veroux P. Contamination of preservation fluid in kidney transplantation: single-center analysis. Transplant Proc. 2010;42(4):1043–5. doi: 10.1016/j.transproceed.2010.03.041.PubMedCrossRefGoogle Scholar
  39. 39.
    Janny S, Bert F, Dondero F, Durand F, Guerrini P, Merckx P, Nicolas-Chanoine MH, Belghiti J, Mantz J, Paugam-Burtz C. Microbiological findings of culture-positive preservation fluid in liver transplantation. Transpl Infect Dis. 2011;13(1):9–14. doi: 10.1111/j.1399-3062.2010.00558.x.PubMedCrossRefGoogle Scholar
  40. 40.
    Albano L, Bretagne S, Mamzer-Bruneel MF, Kacso I, Desnos-Ollivier M, Guerrini P, Le Luong T, Cassuto E, Dromer F, Lortholary O. Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France. Clin Infect Dis. 2009;48(2):194–202. doi: 10.1086/595688.PubMedCrossRefGoogle Scholar
  41. 41.
    Lacroix C, Gicquel A, Sendid B, Meyer J, Accoceberry I, Francois N, Morio F, Desoubeaux G, Chandenier J, Kauffmann-Lacroix C, Hennequin C, Guitard J, Nassif X, Bougnoux ME. Evaluation of two matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems for the identification of Candida species. Clin Microbiol Infect. 2014;20(2):153–8. doi: 10.1111/1469-0691.12210.PubMedCrossRefGoogle Scholar
  42. 42.
    Tan KE, Ellis BC, Lee R, Stamper PD, Zhang SX, Carroll KC. Prospective evaluation of a matrix-assisted laser desorption ionization-time of flight mass spectrometry system in a hospital clinical microbiology laboratory for identification of bacteria and yeasts: a bench-by-bench study for assessing the impact on time to identification and cost-effectiveness. J Clin Microbiol. 2012;50(10):3301–8. doi: 10.1128/jcm.01405-12.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Wilson DA, Joyce MJ, Hall LS, Reller LB, Roberts GD, Hall GS, Alexander BD, Procop GW. Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. J Clin Microbiol. 2005;43(6):2909–12. doi: 10.1128/jcm.43.6.2909-2912.2005.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Hall L, Le Febre KM, Deml SM, Wohlfiel SL, Wengenack NL. Evaluation of the Yeast Traffic Light PNA FISH probes for identification of Candida species from positive blood cultures. J Clin Microbiol. 2012;50(4):1446–8. doi: 10.1128/jcm.06148-11.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015;60(6):892–9. doi: 10.1093/cid/ciu959.PubMedCrossRefGoogle Scholar
  46. 46.
    Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56(9):1284–92. doi: 10.1093/cid/cit006.PubMedCrossRefGoogle Scholar
  47. 47.
    Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. β-d-Glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52(6):750–70. doi: 10.1093/cid/ciq206.PubMedCrossRefGoogle Scholar
  48. 48.
    Wheat LJ. Approach to the diagnosis of invasive aspergillosis and candidiasis. Clin Chest Med. 2009;30(2):367–77. doi: 10.1016/j.ccm.2009.02.012. viii.PubMedCrossRefGoogle Scholar
  49. 49.
    Levesque E, El Anbassi S, Sitterle E, Foulet F, Merle JC, Botterel F. Contribution of (1,3)-beta-d-glucan to diagnosis of invasive candidiasis after liver transplantation. J Clin Microbiol. 2015;53(3):771–6. doi: 10.1128/jcm.03018-14.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB. The (1,3)β-d-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol. 2010;48(11):4083–8. doi: 10.1128/jcm.01183-10.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011;49(2):665–70. doi: 10.1128/jcm.01602-10.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Gavalda J, Meije Y, Fortun J, Roilides E, Saliba F, Lortholary O, Munoz P, Grossi P, Cuenca-Estrella M, ESCMID Study Group for Infections in Compromised Hosts (ESGICH). Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20 Suppl 7:27–48. doi: 10.1111/1469-0691.12660.PubMedCrossRefGoogle Scholar
  53. 53.
    Pappas PG, Kauffman CA, Andes D, Benjamin Jr DK, Calandra TF, Edwards Jr JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–35. doi: 10.1086/596757.PubMedCrossRefGoogle Scholar
  54. 54.
    Silveira FP, Kusne S, AST Infectious Diseases Community of Practice. Candida infections in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:220–7. doi: 10.1111/ajt.12114.PubMedCrossRefGoogle Scholar
  55. 55.
    Pappas PG, Kauffman C, Andes D, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2015;62:e1–50.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56(12):1724–32. doi: 10.1093/cid/cit136.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014;59(6):819–25. doi: 10.1093/cid/ciu407.PubMedCrossRefGoogle Scholar
  58. 58.
    Cleveland AA, Harrison LH, Farley MM, Hollick R, Stein B, Chiller TM, Lockhart SR, Park BJ. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008–2013: results from population-based surveillance. PLoS One. 2015;10(3), e0120452. doi: 10.1371/journal.pone.0120452.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Matsumoto E, Boyken L, Tendolkar S, McDanel J, Castanheira M, Pfaller M, Diekema D. Candidemia surveillance in Iowa: emergence of echinocandin resistance. Diagn Microbiol Infect Dis. 2014;79(2):205–8. doi: 10.1016/j.diagmicrobio.2014.02.016.PubMedCrossRefGoogle Scholar
  60. 60.
    Marti-Carrizosa M, Sanchez-Reus F, March F, Canton E, Coll P. Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2015;59(6):3570–3. doi: 10.1128/aac.04922-14.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26(12):1730–44. doi: 10.1592/phco.26.12.1730.PubMedCrossRefGoogle Scholar
  62. 62.
    Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy. 2010;30(8):842–54. doi: 10.1592/phco.30.8.842.PubMedCrossRefGoogle Scholar
  63. 63.
    Sun HY, Cacciarelli TV, Singh N. Identifying a targeted population at high risk for infections after liver transplantation in the MELD era. Clin Transplant. 2011;25(3):420–5. doi: 10.1111/j.1399-0012.2010.01262.x.PubMedCrossRefGoogle Scholar
  64. 64.
    Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl. 2006;12(5):850–8. doi: 10.1002/lt.20690.PubMedCrossRefGoogle Scholar
  65. 65.
    Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131(10):729–37.PubMedCrossRefGoogle Scholar
  66. 66.
    Lumbreras C, Cuervas-Mons V, Jara P, del Palacio A, Turrion VS, Barrios C, Moreno E, Noriega AR, Paya CV. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis. 1996;174(3):583–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Fortun J, Martin-Davila P, Montejo M, Munoz P, Cisneros JM, Ramos A, Aragon C, Blanes M, San Juan R, Gavalda J, Llinares P, GESITRA Study Group. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation. 2009;87(3):424–35. doi: 10.1097/TP.0b013e3181932e76.PubMedCrossRefGoogle Scholar
  68. 68.
    Winston DJ, Limaye AP, Pelletier S, Safdar N, Morris MI, Meneses K, Busuttil RW, Singh N. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant. 2014;14(12):2758–64. doi: 10.1111/ajt.12963.PubMedCrossRefGoogle Scholar
  69. 69.
    Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant. 2008;8(2):426–31. doi: 10.1111/j.1600-6143.2007.02089.x.PubMedCrossRefGoogle Scholar
  70. 70.
    Guaraldi G, Cocchi S, Codeluppi M, Di Benedetto F, De Ruvo N, Masetti M, Venturelli C, Pecorari M, Pinna AD, Esposito R. Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients. Transplantation. 2005;80(12):1742–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Benedetti E, Gruessner AC, Troppmann C, Papalois BE, Sutherland DE, Dunn DL, Gruessner RW. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J Am Coll Surg. 1996;183(4):307–16.PubMedGoogle Scholar
  72. 72.
    McMullan BJ, Sorrell TC, Chen SC. Cryptococcus gattii infections: contemporary aspects of epidemiology, clinical manifestations and management of infection. Future Microbiol. 2013;8(12):1613–31. doi: 10.2217/fmb.13.123.PubMedCrossRefGoogle Scholar
  73. 73.
    Sun HY, Wagener MM, Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clin Infect Dis. 2009;48(11):1566–76. doi: 10.1086/598936.PubMedCrossRefGoogle Scholar
  74. 74.
    Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis. 2001;7(3):375–81. doi: 10.3201/eid0703.010302.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100. doi: 10.1086/651263.PubMedCrossRefGoogle Scholar
  76. 76.
    Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, del Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Munoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Wagener MM, Husain S, Cryptococcal Collaborative Transplant Study Group. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis. 2007;195(5):756–64. doi: 10.1086/511438.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Baddley JW, Schain DC, Gupte AA, Lodhi SA, Kayler LK, Frade JP, Lockhart SR, Chiller T, Bynon Jr JS, Bower WA. Transmission of Cryptococcus neoformans by organ transplantation. Clin Infect Dis. 2011;52(4):e94–8. doi: 10.1093/cid/ciq216.PubMedCrossRefGoogle Scholar
  78. 78.
    Sun HY, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, Somani J, Gupta KL, del Busto R, Pruett TL, Sifri CD, Limaye AP, John GT, Klintmalm GB, Pursell K, Stosor V, Morris MI, Dowdy LA, Munoz P, Kalil AC, Garcia-Diaz J, Orloff SL, House AA, Houston SH, Wray D, Huprikar S, Johnson LB, Humar A, Razonable RR, Fisher RA, Husain S, Wagener MM, Singh N, Cryptococcal Collaborative Transplant Study Group. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. Clin Infect Dis. 2010;51(9):1062–9. doi: 10.1086/656584.PubMedCrossRefGoogle Scholar
  79. 79.
    Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol. 1999;37(10):3204–9.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Chen LC, Goldman DL, Doering TL, Pirofski L, Casadevall A. Antibody response to Cryptococcus neoformans proteins in rodents and humans. Infect Immun. 1999;67(5):2218–24.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L, Niang R, Casadevall A. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics. 2001;107(5), E66.PubMedCrossRefGoogle Scholar
  82. 82.
    Davis J, Zheng WY, Glatman-Freedman A, Ng JA, Pagcatipunan MR, Lessin H, Casadevall A, Goldman DL. Serologic evidence for regional differences in pediatric cryptococcal infection. Pediatr Infect Dis J. 2007;26(6):549–51. doi: 10.1097/INF.0b013e318047e073.PubMedCrossRefGoogle Scholar
  83. 83.
    Saha DC, Goldman DL, Shao X, Casadevall A, Husain S, Limaye AP, Lyon M, Somani J, Pursell K, Pruett TL, Singh N. Serologic evidence for reactivation of cryptococcosis in solid-organ transplant recipients. Clin Vaccine Immunol. 2007;14(12):1550–4. doi: 10.1128/CVI.00242-07.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    O'Meara TR, Alspaugh JA. The Cryptococcus neoformans capsule: a sword and a shield. Clin Microbiol Rev. 2012;25(3):387–408. doi: 10.1128/cmr.00001-12.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Zaragoza O, Chrisman CJ, Castelli MV, Frases S, Cuenca-Estrella M, Rodriguez-Tudela JL, Casadevall A. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol. 2008;10(10):2043–57. doi: 10.1111/j.1462-5822.2008.01186.x.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Farmer SG, Komorowski RA. Histologic response to capsule-deficient Cryptococcus neoformans. Arch Pathol. 1973;96(6):383–7.PubMedGoogle Scholar
  87. 87.
    Chang YC, Kwon-Chung KJ. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol. 1994;14(7):4912–9.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Brizendine KD, Baddley JW, Pappas PG. Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status. PLoS One. 2013;8(3), e60431. doi: 10.1371/journal.pone.0060431.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, del Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Munoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Wagener MM, Husain S. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis. 2008;46(2):e12–8. doi: 10.1086/524738.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Mueller NJ, Fishman JA. Asymptomatic pulmonary cryptococcosis in solid organ transplantation: report of four cases and review of the literature. Transpl Infect Dis. 2003;5(3):140–3.PubMedCrossRefGoogle Scholar
  91. 91.
    Baddley JW, Perfect JR, Oster RA, Larsen RA, Pankey GA, Henderson H, Haas DW, Kauffman CA, Patel R, Zaas AK, Pappas PG. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis. 2008;27(10):937–43. doi: 10.1007/s10096-008-0529-z.PubMedCrossRefGoogle Scholar
  92. 92.
    Vilchez R, Shapiro R, McCurry K, Kormos R, Abu-Elmagd K, Fung J, Kusne S. Longitudinal study of cryptococcosis in adult solid-organ transplant recipients. Transpl Int. 2003;16(5):336–40. doi: 10.1007/s00147-002-0541-7.PubMedCrossRefGoogle Scholar
  93. 93.
    Vilchez RA, Linden P, Lacomis J, Costello P, Fung J, Kusne S. Acute respiratory failure associated with pulmonary cryptococcosis in non-aids patients. Chest. 2001;119(6):1865–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Baddley JW, Forrest GN. Cryptococcosis in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:242–9. doi: 10.1111/ajt.12116.PubMedCrossRefGoogle Scholar
  95. 95.
    Osawa R, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, Somani J, Gupta KL, Del Busto R, Pruett TL, Sifri CD, Limaye AP, John GT, Klintmalm GB, Pursell K, Stosor V, Morris MI, Dowdy LA, Munoz P, Kalil AC, Garcia-Diaz J, Orloff S, House AA, Houston S, Wray D, Huprikar S, Johnson LB, Humar A, Razonable RR, Fisher RA, Husain S, Wagener MM, Singh N. Identifying predictors of central nervous system disease in solid organ transplant recipients with cryptococcosis. Transplantation. 2010;89(1):69–74. doi: 10.1097/TP.0b013e3181bcda41.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Davis JA, Horn DL, Marr KA, Fishman JA. Central nervous system involvement in cryptococcal infection in individuals after solid organ transplantation or with AIDS. Transpl Infect Dis. 2009;11(5):432–7. doi: 10.1111/j.1399-3062.2009.00424.x.PubMedCrossRefGoogle Scholar
  97. 97.
    Wu G, Vilchez RA, Eidelman B, Fung J, Kormos R, Kusne S. Cryptococcal meningitis: an analysis among 5,521 consecutive organ transplant recipients. Transpl Infect Dis. 2002;4(4):183–8.PubMedCrossRefGoogle Scholar
  98. 98.
    Singh N, Lortholary O, Dromer F, Alexander BD, Gupta KL, John GT, del Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Munoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Wagener MM, Husain S, Cryptococcal Collaborative Transplant Study Group. Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation. 2008;86(5):647–51. doi: 10.1097/TP.0b013e3181814e76.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Sun HY, Alexander BD, Huprikar S, Forrest GN, Bruno D, Lyon GM, Wray D, Johnson LB, Sifri CD, Razonable RR, Morris MI, Stoser V, Wagener MM, Singh N. Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression. Clin Infect Dis. 2015;60(1):36–44. doi: 10.1093/cid/ciu711.PubMedCrossRefGoogle Scholar
  100. 100.
    Sun HY, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, Somani J, Gupta KL, Del Busto R, Pruett TL, Sifri CD, Limaye AP, John GT, Klintmalm GB, Pursell K, Stosor V, Morris MI, Dowdy LA, Munoz P, Kalil AC, Garcia-Diaz J, Orloff SL, House AA, Houston SH, Wray D, Huprikar S, Johnson LB, Humar A, Razonable RR, Fisher RA, Husain S, Wagener MM, Singh N, Cryptococcal Collaborative Transplant Study Group. Cutaneous cryptococcosis in solid organ transplant recipients. Med Mycol. 2010;48(6):785–91. doi: 10.3109/13693780903496617.PubMedCrossRefGoogle Scholar
  101. 101.
    Hellman RN, Hinrichs J, Sicard G, Hoover R, Golden P, Hoffsten P. Cryptococcal pyelonephritis and disseminated cryptococcosis in a renal transplant recipient. Arch Intern Med. 1981;141(1):128–30.PubMedCrossRefGoogle Scholar
  102. 102.
    Siddiqui TJ, Zamani T, Parada JP. Primary cryptococcal prostatitis and correlation with serum prostate specific antigen in a renal transplant recipient. J Infect. 2005;51(3):e153–7. doi: 10.1016/j.jinf.2004.12.005.PubMedCrossRefGoogle Scholar
  103. 103.
    Binnicker MJ, Jespersen DJ, Bestrom JE, Rollins LO. Comparison of four assays for the detection of cryptococcal antigen. Clin Vaccine Immunol. 2012;19(12):1988–90. doi: 10.1128/cvi.00446-12.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, Longley N, Harrison TS, Kozel TR. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011;53(10):1019–23. doi: 10.1093/cid/cir613.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Suwantarat N, Dalton JB, Lee R, Green R, Memon W, Carroll KC, Riedel S, Zhang SX. Large-scale clinical validation of a lateral flow immunoassay for detection of cryptococcal antigen in serum and cerebrospinal fluid specimens. Diagn Microbiol Infect Dis. 2015;82(1):54–6. doi: 10.1016/j.diagmicrobio.2015.01.012.PubMedCrossRefGoogle Scholar
  106. 106.
    Aberg JA, Mundy LM, Powderly WG. Pulmonary cryptococcosis in patients without HIV infection. Chest. 1999;115(3):734–40.PubMedCrossRefGoogle Scholar
  107. 107.
    Bennett JE, Dolin R, Blaser MJ, Mandell GL, Douglas RG. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 8th ed. 2015.Google Scholar
  108. 108.
    Chen SC-A, Meyer W, Sorrell TC. Cryptococcus gattii Infections. Clin Microbiol Rev. 2014;27(4):980–1024. doi: 10.1128/cmr.00126-13.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol. 1982;15(3):535–7.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O, French Cryptococcosis Study Group. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One. 2008;3(8), e2870. doi: 10.1371/journal.pone.0002870.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992;326(2):83–9. doi: 10.1056/nejm199201093260202.PubMedCrossRefGoogle Scholar
  112. 112.
    van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderly WG, Dismukes WE. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997;337(1):15–21. doi: 10.1056/nejm199707033370103.PubMedCrossRefGoogle Scholar
  113. 113.
    Sun HY, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, Somani J, Gupta KL, del Busto R, Pruett TL, Sifri CD, Limaye AP, John GT, Klintmalm GB, Pursell K, Stosor V, Morris MI, Dowdy LA, Munoz P, Kalil AC, Garcia-Diaz J, Orloff S, House AA, Houston S, Wray D, Huprikar S, Johnson LB, Humar A, Razonable RR, Husain S, Singh N. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis. 2009;49(11):1721–8. doi: 10.1086/647948.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50(3):291–322. doi: 10.1086/649858.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Kraus PR, Nichols CB, Heitman J. Calcium- and calcineurin-independent roles for calmodulin in Cryptococcus neoformans morphogenesis and high-temperature growth. Eukaryot Cell. 2005;4(6):1079–87. doi: 10.1128/ec.4.6.1079-1087.2005.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Cruz MC, Del Poeta M, Wang P, Wenger R, Zenke G, Quesniaux VF, Movva NR, Perfect JR, Cardenas ME, Heitman J. Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother. 2000;44(1):143–9.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Kontoyiannis DP, Lewis RE, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, Del Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Munoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Albert ND, Wagener MM, Singh N. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother. 2008;52(2):735–8. doi: 10.1128/AAC.00990-07.PubMedCrossRefGoogle Scholar
  118. 118.
    Park MK, Hospenthal DR, Bennett JE. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis. 1999;28(3):629–33. doi: 10.1086/515161.PubMedCrossRefGoogle Scholar
  119. 119.
    Woodworth GF, McGirt MJ, Williams MA, Rigamonti D. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis. Surg Neurol. 2005;63(6):529–31. doi: 10.1016/j.surneu.2004.08.069. discussion 531–522.PubMedCrossRefGoogle Scholar
  120. 120.
    Newton PN, le Thai H, Tip NQ, Short JM, Chierakul W, Rajanuwong A, Pitisuttithum P, Chasombat S, Phonrat B, Maek ANW, Teaunadi R, Lalloo DG, White NJ. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis. 2002;35(6):769–72. doi: 10.1086/342299.PubMedCrossRefGoogle Scholar
  121. 121.
    Graybill JR, Sobel J, Saag M, van Der Horst C, Powderly W, Cloud G, Riser L, Hamill R, Dismukes W. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000;30(1):47–54. doi: 10.1086/313603.PubMedCrossRefGoogle Scholar
  122. 122.
    Lanternier F, Chandesris MO, Poiree S, Bougnoux ME, Mechai F, Mamzer-Bruneel MF, Viard JP, Galmiche-Rolland L, Lecuit M, Lortholary O. Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient. Am J Transplant. 2007;7(12):2826–8. doi: 10.1111/j.1600-6143.2007.01994.x.PubMedCrossRefGoogle Scholar
  123. 123.
    Legris T, Massad M, Purgus R, Vacher-Coponat H, Ranque S, Girard N, Berland Y, Moal V. Immune reconstitution inflammatory syndrome mimicking relapsing cryptococcal meningitis in a renal transplant recipient. Transpl Infect Dis. 2011;13(3):303–8. doi: 10.1111/j.1399-3062.2010.00592.x.PubMedCrossRefGoogle Scholar
  124. 124.
    Singh N, Lortholary O, Alexander BD, Gupta KL, John GT, Pursell K, Munoz P, Klintmalm GB, Stosor V, delBusto R, Limaye AP, Somani J, Lyon M, Houston S, House AA, Pruett TL, Orloff S, Humar A, Dowdy L, Garcia-Diaz J, Fisher RA, Husain S. Allograft loss in renal transplant recipients with Cryptococcus neoformans associated immune reconstitution syndrome. Transplantation. 2005;80(8):1131–3. doi: 10.1097/01.tp.0000180530.17683.02.PubMedCrossRefGoogle Scholar
  125. 125.
    Boulware DR, Bonham SC, Meya DB, Wiesner DL, Park GS, Kambugu A, Janoff EN, Bohjanen PR. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis. 2010;202(6):962–70. doi: 10.1086/655785.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Baddley J, Klausing B, Brizendine K, Kumar V, Julian B, Eckhoff D, Tallaj J, Wille K, Moser S, Pappas P. Treatment of cryptococcosis in solid-organtransplant recipients: relapse is rare after discontinuation of therapy. Am J Transplant. 2013;13:344.CrossRefGoogle Scholar
  127. 127.
    Colombo AL, Padovan AC, Chaves GM. Current knowledge of Trichosporon spp. and Trichosporonosis. Clin Microbiol Rev. 2011;24(4):682–700. doi: 10.1128/cmr.00003-11.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Girmenia C, Pagano L, Martino B, D'Antonio D, Fanci R, Specchia G, Melillo L, Buelli M, Pizzarelli G, Venditti M, Martino P. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol. 2005;43(4):1818–28. doi: 10.1128/jcm.43.4.1818-1828.2005.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Almeida Junior JN, Song AT, Campos SV, Strabelli TM, Del Negro GM, Figueiredo DS, Motta AL, Rossi F, Guitard J, Benard G, Hennequin C. Invasive Trichosporon infection in solid organ transplant patients: a report of two cases identified using IGS1 ribosomal DNA sequencing and a review of the literature. Transpl Infect Dis. 2014;16(1):135–40. doi: 10.1111/tid.12179.PubMedCrossRefGoogle Scholar
  130. 130.
    Iturrieta-Gonzalez IA, Padovan AC, Bizerra FC, Hahn RC, Colombo AL. Multiple species of Trichosporon produce biofilms highly resistant to triazoles and amphotericin B. PLoS One. 2014;9(10), e109553. doi: 10.1371/journal.pone.0109553.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 2004;10 Suppl 1:48–66.PubMedCrossRefGoogle Scholar
  132. 132.
    Yang MF, Gao HN, Li LJ. A fatal case of Trichosporon asahii fungemia and pneumonia in a kidney transplant recipient during caspofungin treatment. Ther Clin Risk Manag. 2014;10:759–62. doi: 10.2147/tcrm.s67299.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E, Cano V, Tapia C, Perkins A, Gomez-Lopez A, Rodero L, Cuenca-Estrella M. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother. 2005;49(10):4026–34. doi: 10.1128/aac.49.10.4026-4034.2005.PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011;11(2):142–51. doi: 10.1016/s1473-3099(10)70218-8.PubMedCrossRefGoogle Scholar
  135. 135.
    Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev. 1995;8(4):462–78.PubMedPubMedCentralGoogle Scholar
  136. 136.
    Tuon FF, Costa SF. Rhodotorula infection. A systematic review of 128 cases from literature. Rev Iberoam Micol. 2008;25(3):135–40.PubMedCrossRefGoogle Scholar
  137. 137.
    Tuon FF, de Almeida GM, Costa SF. Central venous catheter-associated fungemia due to Rhodotorula spp.—a systematic review. Med Mycol. 2007;45(5):441–7. doi: 10.1080/13693780701381289.PubMedCrossRefGoogle Scholar
  138. 138.
    Zaas AK, Boyce M, Schell W, Lodge BA, Miller JL, Perfect JR. Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J Clin Microbiol. 2003;41(11):5233–5.PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Riedel DJ, Johnson JK, Forrest GN. Rhodotorula glutinis fungemia in a liver-kidney transplant patient. Transpl Infect Dis. 2008;10(3):197–200. doi: 10.1111/j.1399-3062.2007.00265.x.PubMedCrossRefGoogle Scholar
  140. 140.
    Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, Fu W, Colombo AL, Rodriguez-Noriega E. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007;45(6):1735–45. doi: 10.1128/jcm.00409-07.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20(4):695–704. doi: 10.1128/cmr.00014-07.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  1. 1.Division of Infectious Diseases, Department of MedicineUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations